Pluri Inc. (PLUR) - Total Assets
Based on the latest financial reports, Pluri Inc. (PLUR) holds total assets worth $30.60 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of Pluri Inc. for net asset value and shareholders' equity analysis.
Pluri Inc. - Total Assets Trend (2002–2025)
This chart illustrates how Pluri Inc.'s total assets have evolved over time, based on quarterly financial data.
Pluri Inc. - Asset Composition Analysis
Current Asset Composition (June 2025)
Pluri Inc.'s total assets of $30.60 Million consist of 57.1% current assets and 42.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 15.2% |
| Accounts Receivable | $722.00K | 1.9% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $2.79 Million | 7.2% |
| Goodwill | $3.14 Million | 8.1% |
Asset Composition Trend (2002–2025)
This chart illustrates how Pluri Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Pluri Inc. (PLUR) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pluri Inc.'s current assets represent 57.1% of total assets in 2025, an increase from 5.8% in 2002.
- Cash Position: Cash and equivalents constituted 15.2% of total assets in 2025, up from 5.8% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 15.0% of total assets, an increase from 0.0% in 2002.
- Asset Diversification: The largest asset category is goodwill at 8.1% of total assets.
Pluri Inc. Competitors by Total Assets
Key competitors of Pluri Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Pluri Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.43 | 5.04 | 5.02 |
| Quick Ratio | 0.43 | 5.04 | 5.02 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-18.54 Million | $17.93 Million | $39.90 Million |
Pluri Inc. - Advanced Valuation Insights
This section examines the relationship between Pluri Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 306.56 |
| Latest Market Cap to Assets Ratio | 0.71 |
| Asset Growth Rate (YoY) | -2.1% |
| Total Assets | $38.68 Million |
| Market Capitalization | $27.32 Million USD |
Valuation Analysis
Below Book Valuation: The market values Pluri Inc.'s assets below their book value (0.71x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Pluri Inc.'s assets decreased by 2.1% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Pluri Inc. (2002–2025)
The table below shows the annual total assets of Pluri Inc. from 2002 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $38.68 Million | -2.14% |
| 2024-06-30 | $39.53 Million | -22.19% |
| 2023-06-30 | $50.80 Million | -25.37% |
| 2022-06-30 | $68.06 Million | -27.23% |
| 2021-06-30 | $93.54 Million | +42.74% |
| 2020-06-30 | $65.53 Million | +109.30% |
| 2019-06-30 | $31.31 Million | -19.64% |
| 2018-06-30 | $38.96 Million | +3.80% |
| 2017-06-30 | $37.53 Million | -18.30% |
| 2016-06-30 | $45.94 Million | -32.59% |
| 2015-06-30 | $68.16 Million | -7.93% |
| 2014-06-30 | $74.02 Million | +8.35% |
| 2013-06-30 | $68.32 Million | +44.07% |
| 2012-06-30 | $47.42 Million | +3.05% |
| 2011-06-30 | $46.02 Million | +718.50% |
| 2010-06-30 | $5.62 Million | +25.97% |
| 2009-06-30 | $4.46 Million | +24.53% |
| 2008-06-30 | $3.58 Million | -46.72% |
| 2007-06-30 | $6.73 Million | +96.42% |
| 2006-06-30 | $3.42 Million | +30.71% |
| 2005-06-30 | $2.62 Million | +90.24% |
| 2004-06-30 | $1.38 Million | +38.47% |
| 2003-06-30 | $994.59K | +5914.72% |
| 2002-06-30 | $16.54K | -- |
About Pluri Inc.
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. The company's product candidates include PLX-PAD,… Read more